Student Directory

Francis LeBlanc

Class Year: G4



  • M.D./Ph.D. Program


Contact Information:


Biographical Information:

Hometown: Cambridge, Ontario, Canada



Undergraduate Education:  BS/08 Chemistry & Physiology/U of W. Ontario


Research Interests:

Research Interest: drug discovery, leukemia and lymphoma and other blood disorders, sphingolipid signaling
Graduate Program: Molecular Medicine


Description: LGL leukemia is a rare proliferative disorder with two classifications - CD3+T-LGL and CD3-/NK-LGL.  These patients typically present with various cytopenias leading to complications such as anemia and chronic infection associated with neutropenia.  In addition, there is an unusual association with a variety of autoimmune diseases.  My project focuses on the NK-LGL subtype and will investigate the sphingolipid rheostat and it's role in leukemia pathogenesis; specifically sphingosine-1-phosphat signaling through S1PR5 and it's role as a survival pathway.  This will hopefully uncover possible therapeutic targets as NK-LGL is currently an incurable disease, with death occurring in the acute form within a few months of diagnosis.

Meeting Presentations
  • 2012
    American Society of Hematology (ASH), Atlanta, GA



Ding W, You H, Dang H, LeBlanc F, Galicia V, Lu SC, Stiles B, Rountree CB (2010) Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion Hepatology 52(3):945-53

LeBlanc F, Zhang D, Liu X, Loughran Jr. TP (2012) LGL leukemia:  From dysregulated pathways to therapeutic targets Future Oncology 8(7):1-15

Jerez A, Clemente MJ, Makishima H, Koskela H, LeBlanc F, Ng KP, Olson T, Przychodzen B, Afable M, Gomez-Segui I, Guinta K, Durkin L, Hsi ED, McGraw K, Zhang D, Wlodarski MW, Porkka K, Sekeres MA, List A, Mustjoki S, Loughran TP, Maciejewski JP (2012) STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T cell large granular lymphocyte leukemia. Blood 120:3048-57

LeBlanc FR, Hasanali ZS, Loughran TP Jr. (2013) Does IL-15 have a causative role in large granular lymphocyte leukemia? Immunotherapy 5(3):231-4




Francis LeBlanc


Related Links:


Media interested in contacting the above person should contact the Office of Marketing and Communications at 717-531-8606.